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Abstract
Diabetic retinopathy (DR) is one of the most common microvascular complications of diabetes mellitus (DM) and a leading cause of blindness in wor-
king-age adults in developed countries. Numerous investigations have recognised inflammation and angiogenesis as important factors in the deve-
lopment of this complication of diabetes. Current methods of DR treatment are predominantly used at advanced stages of the disease and could be 
associated with serious side effects. Therefore, new diagnostic methods are needed in order to identify the initial stages of DR as well as monitoring 
the effects of applied therapy. Biochemical biomarkers are molecules found in blood or other biological fluid and tissue that indicate the existence of 
an abnormal condition or disease. They could be a valuable tool in detecting early stages of DR, identifying patients most susceptible to retinopathy 
progression and monitoring treatment outcomes. Biomarkers related to DR can be measured in the blood, retina, vitreous, aqueous humour and 
recently in tears. As the retina represents a small part of total body mass, a circulating biomarker for DR needs to be highly specific. Local biomarkers 
are more reliable as indicators of the retinal pathology; however, obtaining a sample of aqueous humour, vitreous or retina is an invasive procedure 
with potential serious complications. As a non-invasive novel method, tear analysis offers a promising direction in further research for DR biomarker 
detection. The aim of this paper is to review systemic and local inflammatory and angiogenic biomarkers relevant to this sight threatening diabetic 
complication.
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Review
Introduction
Diabetic retinopathy (DR) is one of the most com-
mon microvascular complications of diabetes mel-
litus (DM) and a leading cause of visual impair-
ment and preventable blindness in working-age 
adults in developed countries (1). It is character-
ized by the occurrence of microaneurysms, in-
creased vascular permeability, capillary occlusion, 
fibrous and neovascular proliferation. Diabetic 
retinopathy can be classified as mild, moderate, 
and severe non-proliferative DR (NPDR) and prolif-
erative DR (PDR). At any stage due to increased 
vascular permeability and accumulation of intra- 
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and extracellular fluid within the macula, diabetic 
macular oedema (DME) may appear (2). The over-
all prevalence of any form of DR in the period be-
tween 2015 and 2019 was estimated at 27% con-
sisting of 25.2% having NPDR, 1.4% with PDR, and 
4.6% with DME (1). After 20 years of diabetes dura-
tion, almost all patients with type 1 and more than 
60% of patients with type 2 diabetes developed 
some form of retinopathy (3). Major risk factors for 
DR development are hyperglycaemia, hyperten-
sion, dyslipidaemia, obesity, sleep apnoea, preg-
nancy, DM duration, smoking, and genetic factors 
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(4-10). Various biochemical pathways have been 
involved in the pathogenesis of DR and despite in-
tensive research; it is still not fully understood (9). 
According to current research, DR is considered as 
a neurodegenerative, inflammatory, and microvas-
cular complication of diabetes (9,10). The contribu-
tion of inflammatory processes and angiogenesis 
in structural and molecular alterations associated 
with DR is gaining increasing attention and has 
become the focus of many investigations (10-15).
The primary goal of DR treatment including laser 
photocoagulation, intravitreal pharmacologic 
agents, and vitreous surgery is to improve or pro-
tect vision (7). The most preferred method is in-
traocular pharmacotherapy, particularly the appli-
cation of vascular endothelial growth factor (VEGF) 
inhibitors (5,10,12). Existing methods of DR treat-
ment are predominantly applied at advanced 
stages of the disease and may be associated with 
serious side effects. In the early stages, the only 
available therapeutic approach is strict control of 
modifiable DR risk factors particularly glycaemic, 
blood pressure, and serum lipid concentration 
regulation. Therefore, new diagnostic methods are 
necessary in order to identify the initial stages of 
this diabetic complication and monitoring the ef-
fects of applied therapy (5,11,14,15). Circulating bi-
omarkers could be a valuable tool in detecting 
early stages of DR, identifying patients most sus-
ceptible to its progression and monitoring re-
sponses to applied treatment (4,11,14-16,17).
Extensive research has verified the role of inflam-
mation and angiogenesis in the pathogenesis of 
DR (4,5,6,9-15,18). Changes in the concentrations of 
various pro-inflammatory and angiogenic media-
tors have been found in serum, aqueous humour 
(AH), vitreous, retina, and in the tears of patients 
with DR. Their concentrations are often correlated 
with the degree of DR implicating that they can be 
used as biomarkers (9,10,12-14,19-39). Given that a 
number of these molecules are involved in the for-
mation and development of DR, in this review, we 
have included potential systemic and local bio-
markers which were evaluated based on their role 
in DR pathogenesis.
Inflammation and diabetic retinopathy 
Inflammation has an important role in the patho-
genesis of DR and chronic low-grade inflamma-
tion is present in different stages of DR. It is re-
sponsible for retinal vasculature damage and takes 
part in the development of both major causes of 
visual impairment in diabetes: increased retinal 
vascular permeability (DME) and neovascularisa-
tion (PDR) (4-6,9-15,18).
Diabetes causes increased local and systemic pro-
duction of numerous inflammatory molecules in-
volved in DR development such as vascular adhe-
sion molecules, cytokines, chemokines, transcrip-
tion, and growth factors (5,9-15,18-42). Elevated 
concentrations of these molecules induce activa-
tion and migration of leukocytes and leukostasis 
(4,40,41) with subsequent capillary occlusion, reti-
nal hypoxia, and endothelial cell damage. The re-
sult of these activities is the blood-retinal barrier 
(BRB) breakdown which leads to retinal oedema, 
haemorrhages, exudates, and microaneurysm for-
mation (4,10,12,14,15,18). Activated pericytes are 
also involved in the retinal inflammatory processes 
of DR development. They excrete pro-inflammato-
ry mediators, which direct and accumulate im-
mune cells towards the site of retinal inflammation 
(42). There is growing evidence that retinal neuro-
degeneration may be a relevant pathophysiologi-
cal mechanism of DR development (10,31,43). Reti-
nal glial cells including astrocytes, Müller cells, and 
microglia are responsible for providing structural 
support and maintaining homeostasis in the reti-
na (43). Their dysfunction is involved in the early 
retinal inflammatory process in DR (12). Hypergly-
caemic stress causes activation of microglial cells 
(43). Retinal neurodegeneration and neuronal ap-
optosis developed in the early stages of DR causes 
thinning of the nerve fibre layer and consequent 
visual impairment and visual loss (15).
Inflammatory and angiogenic interaction 
in diabetic retinopathy
Angiogenesis is a well-controlled process regulat-
ed by balancing proangiogenic (VEGF) and antian-
giogenic endogenous factors (23,44). During this 
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process endothelial cell migration and prolifera-
tion with blood vessel maturation and remodel-
ling as well as degradation of extracellular matrix 
takes place. Degradation of the extracellular ma-
trix is a very important part of this activity since it 
regulates the entire process (15,18,22,23,45).
A proangiogenic imbalance causes abnormal 
growth of new fragile and leaky blood vessels 
namely neovascularisation (NV) (18). One of the 
major causes of retinal NV is ischemia however, in-
flammatory cells may also be involved in angio-
genic processes by producing angiogenic cy-
tokines and growth factors (18,41,44). Microvascu-
lar endothelium activated by cytokines and angio-
genic growth factors can express proinflammatory 
molecules involved in leukocyte mobilisation and 
activation (10,18,44-46). Neovascularization and 
inflammation share several common mediators 
and signalling pathways (18,44). Several 
chemokines may act as leukocyte attractants and 
as angiogenic inducers affecting endothelial cells 
(18,22,23,44-46). Thus, angiogenesis and inflam-
mation show an interconnection and it can be as-
sumed that inflammation is involved in the early 
as well as in the advanced stages of DR character-
ised by increased permeability and NV (18,44).
The role of biomarkers in diabetic 
retinopathy management 
Biochemical biomarkers are molecules found in 
blood or other biological fluid and tissue signify-
ing the existence of an abnormal condition or a 
disease however may also be indicators of normal 
biological processes. They may aid in identifying 
individuals who are at higher risk for developing 
the disease, patients with early forms of the dis-
ease, those with a tendency for disease progres-
sion as well as in monitoring the effect of treat-
ment (16,17,47-49). 
Biomarkers for DR in systemic circulation or local 
tissues can be an indicator of pathological pro-
cesses connected with DR based on their role in its 
development. They can be measured in the blood, 
vitreous, retina, AH, and recently in tears (Table 1) 
(16,17,19-39,43-56). The advantage of determining 
biomarkers in the blood is the availability and larg-
er sample volume of the specimen, routine collec-
tion procedures, and standardized analytical tech-
niques as well as the possibility of repetitive analy-
sis. However, as the retina represents a small part 
of total body mass, a circulating biomarker for DR 
must be very specific to be relevant. Local bio-
markers present the more accurate indicators of 
the retinal pathology. However, they are only avail-
able during surgical procedures, and obtaining a 
sample of AH or vitreous is an invasive procedure 
with possible serious complications influencing 
visual function. An additional problem with the lo-
cal specimen is the small sample size and the lack 
of standardized analytical techniques and valida-
tion of data (17,21-23,46,50,51). Some clinical and 
biochemical biomarkers such glycaemia, HbA1c, 
blood pressure, blood lipid concentrations, and 
ocular coherence tomography (OCT) are routinely 
used as biomarkers in the monitoring of patients 
with diabetes. Among pro-inflammatory and an-
giogenic factors, we can single out VEGF which 
has enabled the development of anti-VEGF treat-
ment (14,17,26,36,37,39,54). Many other molecules 
are used in basic science studies investigating the 
pathogenesis of DR or as surrogate end-points in 
preclinical studies that explore new therapy op-
tions (6,47,48).
Since the existing treatment methods of DR are 
generally applied in advanced stages of the dis-
ease, reliable biomarkers for early detection are 
needed to enable timely treatment. Future re-
search should be directed at exploring novel DR 
biomarkers, which should be accessible, non-inva-
sive, economical, and accurate in order to evaluate 
the presence and progression of DR (11,15,17). 
Collection and analysis of ocular 
specimens
Evaluating biomarkers in the systemic circulation 
(Table 2) is a routine procedure at every stage, 
while the same process with ocular samples repre-
sents a challenge. The key problem related to ocu-
lar biomarkers is gathering a sufficient volume of 
ocular specimens such as tears, AH, and vitreous 
for evaluation (Table 3). Thus, it is essential to opti-
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Biomarkers Systemic circulation (references)
Ocular fluids
Tears (references) Aqueous humour (references)
Vitreous fluid 
(references)
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CRP – C-reactive protein. TNF-α – Tumour necrosis factor- alpha. IL-1β – Interleukin-1-beta. IL-6 – Interleukin-6. IL-8 – Interleukin-8. 
IL-12 – Interleukin-12. VEGF –Vascular endothelial growth factor. PEDF – Pigment epithelium-derived factor. PGF – Placental growth 
factor.  ICAM-1 – Intracellular adhesion molecule-1. VCAM-1 –Vascular cell adhesion molecule-1. IGF-1 – Insulin-like growth factor-1. 
TGF-β –Transforming growth factor beta. bFGF – Basic fibroblast growth factor. HGF –Hepatocyte growth factor. CTGF – Connective 
tissue growth factor. RBP4 – Retinol-binding protein 4. CXCL10 – chemokine-10. MCP-1 – Monocyte chemotactic protein-1. CCL5 – 
Chemokine ligand 5.
Table 1. Potential systemic and ocular biomarkers for diabetic retinopathy 
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Biomarker (analytical technique) Serum concentration (pg/mL) Reference
CRP (immunoturbidimetric assay) 5.4 ± 5.8 (19)
TNF-α (ELISA) 1.7 ± 1.4 (50)
IL-1β (ELISA) 0.44 ± 0.13 (65)
IL-6 (ELISA) 3.9 ± 1.2 (50)
IL-8 (Miliplex X-MAP) 3.0 ± 4.6 (69)
IL-12 (Miliplex X-MAP) 1.8 ± 1.6 (50)
VEGF (Miliplex X-MAP) 48.76 ± 76.87 (69)
ICAM-1 (Miliplex X-MAP) 156.83 ± 89.49 (69)
VCAM-1 (Miliplex X-MAP) 900.41 ± 374.81 (69)
E-selectin (Miliplex X-MAP) 36.12 ± 37.62 (69)
MCP-1 (Miliplex X-MAP) 193.69 ± 133.01 (69)
CCL5 (Miliplex X-MAP) 75315.97 ± 63941.70 (69)
CRP – C-reactive protein. TNF- α – Tumour necrosis factor- alpha. IL-1β – Interleukin-1- beta. IL-6 – Interleukin-6. IL-8 – Interleukin-8. 
IL-12 – Interleukin-12. VEGF – Vascular endothelial growth factor. ICAM-1 – Intracellular adhesion molecule-1. VCAM-1 – Vascular cell 
adhesion molecule-1. MCP-1 – monocyte chemotactic protein-1. CCL5 – Chemokine ligand 5. ELISA - Enzyme-linked immunosorbent 






CRP (pg/mL) - - 6.0 ± 2.3† (31)
TNF-α (pg/mL) 2.21 ± 0.04* (30) 4.04 ± 1.83§ (27) 48.33 ± 4.69† (59)
IL-1β (pg/mL) 16.7 ± 3.2† (29) 1.07 ± 1.03§ (27) 1.54 ± 0.14† (59)
IL-6 (pg/mL) 63.3 ± 12.3† (29) 40.64 ± 16.52§ (27) 55.20 ± 21.72† (59)
IL-8 (pg/mL) 87 ± 26† (29) 42.20 ± 33.03§ (27) 121.84 ± 99.26† (59)
IL-12 (pg/mL) - 12.85 ± 7.12* (21) 37.26 ± 15.92† (59)
VEGF (pg/mL) 149.5 ± 10.4‡ (54) 357.02 ± 84.25§ (27) 163.31 ± 63.65† (59)
PEDF (pg/mL) - 1.74 ± 3.68‖ (92) 9.4 ± 1.2* (91)
MCP-1 (pg/mL) 92.2 ± 10.4† (29) 385.57 ± 147.04§ (27) 385.57 ± 147.04† (59)
CCL5 (pg/mL) 35.4 ± 4.6† (29) 1.11 ± 0.35§ (27) 3302.78 ± 1238.95† (59)
CRP - C – reactive protein. TNF-α – Tumour necrosis factor- alpha. IL-1β – Interleukin-1-beta. IL-6 – Interleukin-6. IL-8 – Interleukin-8. 
IL-12 – Interleukin-12. VEGF – Vascular endothelial growth factor. PEDF – Pigment epithelium-derived factor. MCP-1 – monocyte 
chemotactic protein-1. CCL5 – Chemokine ligand 5. *Enzyme linked-immunosorbent assay. †Bead-based multiplex immunoassay 
(Bio-Plex Human Cytokine 27-plex panel). ‡Quantitative sandwich enzyme immunoassay. §ProcartaPlex immunoassay. ‖Western 
blot analysis.  
Table 2. Potential systemic biomarkers for diabetic retinopathy 
Table 3. Potential ocular biomarkers for diabetic retinopathy 
mize collecting, storage, processing, and analysis 
of obtained samples in order to maximize their 
use (47,48). The most readily obtainable ocular 
specimens are tears and conjunctiva, which usual-
ly provide information related to the anterior seg-
ment pathology. There are studies in which DR bi-
omarkers have been determined in tears, but there 
are currently no such studies for the conjunctiva 
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(29,30,54). Diabetic retinopathy biomarkers which 
more accurately reflect the pathology of the pos-
terior segment of the eye, are those determined 
from the AH and vitreous (47,48). However, these 
are difficult to obtain and entail invasive proce-
dures to collect the sample (21-23,26-28,31-34,36-
39,47,48,51-54,56,57).
Tears may be collected by several non-invasive 
methods using absorbent materials such as 
Schirmer strips, minisponges, fire-polished micro-
capillary tubes, and eyewash. Variations in the re-
sults observed between studies can be influenced 
by the differences in sample collection and stor-
age methods (47). During tear sampling, it is es-
sential to avoid activation of the corneal nerves 
and reflex tearing since it can alter the composi-
tion of tear fluid. External factors including the use 
of topical anaesthesia, artificial tears, contact lens 
wear, and collection techniques in general may in-
fluence tear composition and thus affect the inter-
pretation of the results (47,57). 
Whilst tears are collected by non-invasive proce-
dures, AH samples are gathered invasively via 
aqueous taps during cataract surgery or trab-
eculectomy. Collection volumes range from 0.1-
0.25 mL and in most cases may be sufficient for 
only one molecule test and a false negative result 
may occur (58). Contact with other eye structures 
during the collection process may influence the 
results by contaminating samples with non-AH 
proteins (47). 
In order to obtain a larger sample of intraocular 
fluid, vitreous sampling which usually contains 
volumes of 1-2 mL is required. This sample is also 
taken invasively via vitreous taps during vitrecto-
my, by needle aspiration or collection of vitreous 
refluxes using Schirmer strips, microsponges, and 
millipore filters after intravitreal injections (47,59). 
Due to the low volume of ocular sample and limita-
tions of the sampling process itself, it is important 
to set guidelines for the standardization of collec-
tion methods, its processing, and storage to enable 
comparison across studies and increase the reliabil-
ity of the collected data. Studies undertaken to as-
sess sample integrity and reproducibility have 
shown that the duration of sample storage should 
be limited between several days and several weeks 
(47). New protein and gene-based technologies im-
prove sensitivity and enable evaluation of multiple 
biomarkers in small volumes of tear, AH, or vitreous 
samples. Improvement of analytical methods opens 
new opportunities for the use of a single sample for 
multiple biomarker assessments giving consistent 
and reliable results (47,59).
Inflammatory biomarkers of diabetic 
retinopathy 
Given that inflammation has a significant role in 
the pathogenesis of DR inflammatory biomarkers 
have been intensively investigated (10,17,22,24,44-
46,49-52). Various pro-inflammatory factors, such 
as cytokines and chemokines have been identified 
at increased concentrations in ocular fluid and tis-
sue namely retina, vitreous, AH, and tears as well 
as systemic circulation that may be useful as po-
tential biomarkers of DR (19-39,52-54,59-77).
C-reactive protein 
C-reactive protein (CRP) is an acute-phase protein 
as well as a marker of inflammation and tissue 
damage. It is produced in the liver and adipose tis-
sue in response to interleukin 6 (IL-6), IL-1β, and tu-
mour necrosis factor-alpha (TNF-α) activity (9,14). 
The role of CRP in the pathogenesis of DR has 
been extensively investigated however clinical 
studies related to the association between CRP se-
rum and plasma concentrations and DR have ob-
tained diverse results. Some studies confirmed 
that CRP concentrations are associated with DR in 
both DM types, whilst others gave opposing re-
sults (13,49-51,60,78). Several studies showed high-
er concentrations of CRP in patients with PDR in 
comparison to the patients with NPDR and those 
findings may support the results of the meta-anal-
ysis by Song et al. indicating that the CRP concen-
tration may be used as a biomarker of DR severity 
(13,19,49-51,60,78). However, results regarding the 
value of CRP as a biomarker for DR due to incon-
clusive results should be clarified. In a cross-sec-
tional study including 24 patients with PDR con-
ducted by Mallmann et al. (31) increased vitreous 
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concentrations of CRP were found compared to 
the control group of 31 non-diabetic patients. The 
vitreous concentration of CRP was 6.0 ± 2.3 pg/mL 
which is similar to concentrations found in serum 
reported by Tomić et al. (5.4 ± 5.8 pg/mL) and 
Zorena et al. (2.3 ± 1.0 pg/mL) (19,50). 
Tumour necrosis factor-α 
Tumour necrosis factor-α is a proinflammatory cy-
tokine that increases leukocyte adhesion to retinal 
endothelium and leukostasis, the production of re-
active oxygen species (ROS), permeability of retinal 
endothelial cells and is implicated in BRB (4,46,61). 
Increased concentrations of TNF-α have been in-
volved in the development of several chronic in-
flammatory diseases (9,49). Current studies showed 
that patients with DM have higher serum concen-
trations of TNF-α than healthy controls and these 
concentrations correlated with the stage of DR with 
the highest concentrations being found in patients 
with PDR (20,49). Additionally, in the vitreous fluid 
of diabetic patients increased concentrations of 
TNF-α and the TNF-α expression in epiretinal mem-
branes of patients with PDR were found. This con-
firms the importance of local TNF-α production for 
the development of DR (20,46,61,62). In a cross-sec-
tional study with 100 participants, Zorena et al. 
found that the risk of NDR in the paediatric popula-
tion was strongly correlated with serum TNF-α con-
centration (50). In an observational study including 
86 patients, Kocabora et al. reported increased con-
centrations of TNF-α in serum, and AH of patients 
with DME in comparison to healthy controls (51). A 
new approach in the field of retinopathy diagnos-
tics is the assessment of inflammatory mediators in 
tears (53,54). Measurement of TNF-α in tears in a 
prospective study conducted by Costagliola et al. 
showed that TNF-α concentrations were lower in 
the control group than in diabetic patients with its 
concentration being correlated to the severity of DR 
(53). 
Interleukin-6
Interleukin-6 is a multifunctional cytokine that 
regulates inflammation and immune responses, 
by acting on various cell types including leuko-
cytes, endothelial cells, and fibroblasts 
(20,25,52,63). It is involved in increasing vascular 
permeability and stimulation of angiogenesis di-
rectly and indirectly by inducing expression of 
VEGF (9,64). The IL-6 signalling pathway is implicat-
ed in the pathogenesis of several inflammatory 
eye diseases including DR and this association is 
well documented (20,22,23,28,32,52,63,64). Vitre-
ous concentrations of IL-6 are associated with DR 
development and correlates with the severity of 
retinopathy particularly with PDR and DME 
(4,9,20,63,65). Further, several investigations 
showed a positive correlation between serum con-
centrations of IL-6 and the presence and stage of 
DR in both types of DM (20,63,65,66,75). In a cross-
sectional study, including 159 patients with DM 
Shimizu et al. found that serum IL-6 concentrations 
also significantly related to the severity of ME and 
could be a predictor of PDR (75).
Interleukin-1 beta 
Interleukin-1 beta is a key pro-inflammatory cyto-
kine secreted mostly by monocytes and macro-
phages which has a substantial role in inflamma-
tory processes involved in DR development 
(46,64). Interleukin-1 beta is an unstable molecule 
and since it is difficult to detect with commercial 
kits only a few conducted studies exist. The results 
of these studies showed increased concentrations 
of IL-1β in serum and ocular fluids of patients with 
DR and DME (20,27,46,62,65). 
Interleukin-8 
Interleukin-8 or CXCL8 is a pro-inflammatory che-
mokine, which acts as an activator and stimulator 
of chemotaxis for neutrophils, monocytes, and 
lymphocytes and is a powerful promoter of angio-
genesis. Increased concentrations of IL-8 have 
been found in serum as well as vitreous and AH of 
patients with PDR and DME having a specific role 
in ME formation associated with diabetes 
(20,27,28,33,36,46,64).
Cell adhesion molecules 
Cell adhesion molecules (CAMs) are involved in 
leukostasis, in processes of angiogenesis and have 
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a role in the development of vascular complica-
tions (41,46,76). They are increased in extraocular 
and retinal vessels even in the early stages of dia-
betes and DR, causing increased leukocyte adhe-
sion, vascular leakage, capillary nonperfusion, and 
endothelial cell damage (45,46). The most impor-
tant CAMs are intracellular adhesion molecule-1 
(ICAM-1), vascular cell adhesion molecule-1 
(VCAM-1), and E-selectin, which are present in high 
concentrations in the vitreous of patients with PDR 
(66,67). The concentrations of ICAM-1 in the vitre-
ous are even higher in patients with active forms 
of PDR (66). The expression of ICAM-1 is increased 
in the retinal and choroid vessels as well as in the 
fibrovascular membranes of diabetic patients fa-
cilitating the mobilisation of leukocytes (69). In a 
prospective study with 725 African Americans 
with type 1 DM, Roy et al. showed an association 
between baseline plasma ICAM-1 concentrations 
with DME and baseline plasma concentration of E-
selectin with DR progression (69). E-selectin and 
VCAM-1 are also involved in the pathogenesis of 
DR and may both act as angiogenic factors on en-
dothelial cells with a direct positive correlation be-
tween VCAM-1 and the concentration of VEGF 
(18,41,44,67,70). The soluble forms of vascular ad-
hesion molecules were found to be elevated in the 
vitreous and serum of patients with PDR (67,70). 
Their production increased in the presence of high 
concentrations of glucose and proinflammatory 
cytokines such as TNF-α and IL-1β (9,46,69). How-
ever, some investigations question the direct im-
plication of CAMs in the pathogenesis of DR, and 
therefore, further research is necessary to clarify 
their precise role (6,10,12,14).
Retinol-binding protein 4 
Retinol-binding protein 4 (RBP4) is an adipokine 
secreted by hepatocytes and adipose tissue which 
acts as a specific carrier for vitamin A (71). Previous 
studies have suggested that serum RBP4 concen-
trations were associated with insulin resistance, 
metabolic syndrome, impaired glucose tolerance, 
and type 2 diabetes (72-74). It has also been associ-
ated with inflammatory factors such as CRP and 
IL-6 (74). In an animal model, its overexpression 
was shown to be connected with early-onset mi-
croglia activation, progressive retinal degenera-
tion, and increased expression of pro-IL-18 (77). In 
a cross-sectional study, Li et al. found an associa-
tion of elevated plasma concentrations of RBP4 
with DR and vision-threatening DR (VTDR) in 92 
Chinese patients with type 2 diabetes, suggesting 
its possible role in the pathogenesis of DR compli-
cations (78). Since RBP4 stimulates the expression 
of proinflammatory molecules in human retinal 
cells it may be part of the inflammatory pathoge-
netic process of DR development and may be con-
sidered as a biomarker of the early stages of retin-
opathy (71,77). 
Angiogenesis related biomarkers 
Angiogenesis is the process involving the devel-
opment of new a vascular network from pre-exist-
ing blood vessels. It is characterised with abnor-
mal new vessel formation resulting with hypoxia 
and vascular leakage (9,15,18,44). The neovasculari-
sation of the retina represents a typical feature of 
PDR. In the process of angiogenesis, numerous 
mediators are involved with some being consid-
ered as potential biomarkers of DR 
(18,22,32,33,49,63-65,79-100). 
Vascular endothelial growth factor 
Vascular endothelial growth factor (VEGF) is a gly-
coprotein from the family of growth factors, which 
functions as an effective inducer of retinal vascular 
permeability and angiogenesis. It is considered as 
the main angiogenic growth factor implicated in 
DR development (79). The VEGF family consists of 
six proteins: VEGF-A,-B,-C,-D,-E, and placental 
growth factor (PGF) with VEGF-A being the best 
known and most widely used in clinical practice 
(80). VEGF induces retinal ICAM-1 expression and 
retinal leukocyte adhesion leading to BRB break-
down, capillary non-perfusion, and endothelial 
cell damage. The imbalance between VEGF and 
angiogenic inhibitor activity leads to aberrant an-
giogenesis and proliferation in the retina of pa-
tients with DM. Current research results show a 
significant correlation of VEGF in serum and vitre-
ous with DR and DME (22,24,26,37,54,63,65,82-
85,86). Vascular endothelial growth factor and its 
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receptor were found on the epiretinal membrane 
in the eyes of patients with diabetes and a correla-
tion between VEGF concentrations and retinopa-
thy activity was established (37,82). A meta-analy-
sis conducted by Zhou et al. showed that VEGF 
concentrations in the serum correlate to the pres-
ence and severity of retinopathy in diabetic pa-
tients with the conclusion that serum VEGF may 
be a potential biomarker for assessing the devel-
opment and progression of DR (84). However, 
when interpreting the findings, it must be taken 
into account that serum VEGF concentrations may 
be influenced by platelet activation (84). The as-
sessment of VEGF in tears represents an advance-
ment in screening and diagnosis of DR (29,30,51). 
Ang et al. in a comparative cross-sectional study 
evaluated the concentrations of VEGF in tears in 88 
type 2 DM patients (54). Tear samples were collect-
ed using Schirmer strips and measured by en-
zyme-linked immunosorbent assay. Mean tear 
VEGF concentrations were significantly higher in 
the NPDR and PDR groups (114.9 ± 8.6 pg/mL and 
149.5 ± 10.4 pg/mL, respectively) as compared to 
the non-DR group (41.2 ± 11.3 pg/mL, P < 0.001) 
suggesting a significant association with the se-
verity of DR. 
Placental growth factor 
Placental growth factor (PGF) as a member of the 
VEGF family is implicated in pathological angio-
genesis, particularly retinal disorders. It can in-
crease the activity of low concentrations of VEGF 
and indirectly stimulate endothelial cell prolifera-
tion and migration (9,83). Increased concentrations 
of PGF are observed in the vitreous of patients 
with PDR with these concentrations being signifi-
cantly correlated with the concentration of VEGF 
(38,39,79). Animal models show that PGF mediates 
both permeability and NV as well as inflammation 
suggesting that PGF plays an important role in ab-
errant angiogenesis (86). Research studies includ-
ing patients with the diabetic retinal disease 
showed that treatment inhibiting both VEGF and 
PGF provide superior outcomes compared with 
treatment inhibiting only VEGF (88).
Pigment epithelium-derived factor
Pigment epithelium-derived factor (PEDF) is a gly-
coprotein with neuroprotective, neurotrophic, and 
antiangiogenic as well as anti-inflammatory and an-
ti-oxidant activities (89,94). It may inhibit angiogen-
esis directly diminishing the expression of the VEGF 
gene and indirectly by elevating gamma-secretase 
complex activity effects on VEGF-receptor 1 (VEG-
FR-1) (94). Pigment epithelium-derived factor inhib-
its the production of ROS, monocyte chemotactic 
protein-1 (MCP-1), and neutralizes damaging effects 
of the glycation end products. Experimental studies 
show that PEDF inhibits neoangiogenesis under 
conditions where blood concentrations of oxygen 
concentration are normal and stimulates it in hy-
poxic situations (89,90). Previous studies demon-
strated that the concentration of PEDF was lower in 
eyes with DR, particularly in those with PDR. In the 
vitreous of patients with PDR, the concentration of 
a soluble VEGF-R1 (sVEGF-R1) was significantly high-
er whilst the concentration of PEDF was lower when 
compared to patients with diabetes and no signs of 
retinopathy (91). These findings indicated that the 
decreased concentration of PEDF in the eyes might 
be involved in the progression of DR and the de-
gree of retinal NV (91,92).
Insulin-like growth factor-1 
Insulin-like growth factor-1 (IGF-1) is a polypeptide 
hormone that has a similar structure and function 
to insulin and is produced and secreted in the liver, 
fibroblasts, and chondrocytes. It regulates the pro-
liferation and differentiation of several cell types 
(93). It is involved in the regulation, growth, matu-
ration, and functioning of blood vessels and has 
an important function in the pathogenesis of DR. 
The mitotic effect of IGF-1 is the main cause of the 
growth and proliferation of vascular endothelial 
cells. The IGF-1 participates in the activation of 
VEGF in human RPE cells and with its receptor (IGF-
1R) is involved in the pathogenesis or progression 
of proliferative vitreoretinal disorders (14,15). Ex-
perimental studies indicate that IGF-1 stimulates 
the production of VEGF with significantly in-
creased concentrations in the eyes of patients with 
PDR compared to the control group (9,93,94).
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Transforming growth factor beta 
Transforming growth factor beta (TGF-β), a mem-
ber of the family of transforming factors, has im-
munoregulatory activities, and enhances angio-
genesis and chondrogenesis (94). The concentra-
tion of TGF-β showed an association with the se-
verity of microvascular complications and the du-
ration of DM. Patients with DR and NV glaucoma 
had elevated concentrations of TGF-β in serum 
(85,94). Research regarding its concentration in the 
AH showed similar results. Rusnak et al. conducted 
a prospective cohort study of 61 eyes from 56 pa-
tients that suggested that the AH concentrations 
of IL-6, TGFβ-1, and VEGF correlate with the severi-
ty of PDR (85). Patients with NV glaucoma that 
were refractory to treatment showed higher val-
ues of these factors than other PDR patients’ im-
plying that the concentrations of IL-6, TGFβ-1, and 
VEGF are correlated with the severity of PDR. How-
ever, due to a small group of ten patients with NV 
glaucoma, these particular results should be inter-
preted with caution. 
Basic fibroblast growth factor 
Basic fibroblast growth factor (bFGF) is a growth 
factor with mitogen and antigenic activity in-
volved in the survival and maturation of neurons 
and glial cells as well as tissue repair (86). Glial cell 
line-derived neurotrophic factor stimulates Muller 
cells to produce bFGF, which in turn promotes en-
dothelial cell proliferation and VEGF production 
(9,95). Basic fibroblast growth factor receptor is ex-
pressed in the retina and is known to be involved 
in the formation of epiretinal membranes and in 
the pathogenesis of PDR (95).
Hepatocyte growth factor
Hepatocyte growth factor (HGF) and its receptor 
modulate the motility, growth, and morphogene-
sis of various cell types and have angiogenic activ-
ity by inducing the formation of capillary-like tu-
bules (97,98). In serum and vitreous of patients 
with PDR elevated concentrations of HGF were 
found. Shinoda et al. in an observational study re-
ported that HGF in AH obtained from 58 diabetic 
patients during ocular surgery positively correlat-
ed with the stage of DR (99). Intravitreal HGF con-
centrations in PDR patients were significantly 
higher than concentrations found in the control 
group. Canton et al. in their observational study 
concluded that the high vitreous concentrations 
of HGF observed in 17 diabetic patients with PDR 
are not caused by serum diffusion through the 
BRB rather suggests that intraocular synthesis may 
be the main contributing factor (98). 
Interleukin-12 
Interleukin-12 (IL-12) is a cytokine that stimulates 
proliferation, activation, and cytotoxicity of lym-
phocytes T and natural killer (NK) cells. It also stim-
ulates these cells to produce interferon-gamma 
(INF-γ) and TNF-α. Several studies showed that IL-
12 has antiangiogenic effects (21,27,28,94). In vitro 
studies indicate that maintaining the equilibrium 
between pro- and anti-inflammatory factors are 
crucial to sustaining physiological angiogenesis. 
Shifting this balance in favour of the proangiogen-
ic mediators induces pathological angiogenesis 
(81,94). Zorena et al. in a cross-sectional study in-
cluding 126 patients found that in children with 
type 1 DM and retinopathy the serum concentra-
tion of TNF-α was significantly higher and the con-
centration of IL-12 was significantly lower than in 
the group without retinopathy suggesting that in-
creased TNF-α production may be the result of in-
sufficient IL-12 concentrations (81). They proposed 
that the balance between the pro- and antiangio-
genic cytokines might be one of the preventing 
factors in the development of DR and nephropa-
thy in children with diabetes. Further, in an obser-
vational study conducted by Gverović-Antunica et 
al. a significantly higher concentration of IL-12 was 
found in the AH of non-treated DR patients in 
comparison to diabetic patients treated for retin-
opathy, patients without retinopathy or healthy 
controls. Since the serum concentrations of IL-12 
did not differ considerably between the study 
groups the conclusion was that this could be due 
to its local production and secretion (21). 
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Connective tissue growth factor 
Connective tissue growth factor (CTGF) is a cy-
tokine engaged in the stimulation of proliferation, 
angiogenesis, migration, extracellular matrix pro-
duction, cell attachment, survival, and apoptosis. 
It represents a key cell factor that promotes fibro-
sis with several investigations showing that it is 
closely related to DR fibrosis development. CTGF 
promotes the formation of proliferative mem-
branes in PDR and indirectly modulates VEGF ex-
pression. Higher concentrations of CTGF and VEGF 
were found in the vitreous of PDR patients and in 
the PDR stage, the CTGF and VEGF ratio is a strong 
predictor of vascular fibrosis transformation 
(6,9,100).
Conclusion 
Inflammation and angiogenesis play a significant 
role in the pathogenesis of DR. Serum and ocular 
biomarkers, which enable the assessment of the 
presence of inflammatory and angiogenic pro-
cesses represent useful tools for monitoring the 
appearance and progression of DR. In the patho-
genesis of DME and PDR, VEGF plays an important 
role with anti-VEGF treatment being an estab-
lished method of DR therapy. Some patients re-
spond unsatisfactorily to anti-VEGF treatment with 
the assumption that these patients although hav-
ing PDR, have undetectable concentrations of 
VEGF in the vitreous fluid (55). This further indi-
cates that VEGF-independent pathways could play 
a primary role in DR pathogenesis in these particu-
lar patients and the improvement of therapeutic 
methods for blocking other pro-inflammatory and 
proangiogenic factors could be effective. The 
identification of reliable and accessible biomarkers 
for DR would provide valuable information that 
could be used for the development of new thera-
peutic strategies applying an individual approach. 
In this regard, circulating or ocular biomarkers 
could be particularly useful in detecting patients 
who would benefit from the existing therapy. 
Based on this, new methods of treatment could be 
developed and directed towards personalized 
medicine. 
Limitations in searching for biomarkers of DR 
could be the fact that their plasma concentrations 
may reflect the systemic effects of diabetes rather 
than specific damage in the retina. As such, the fo-
cus should shift to assessing circulating concentra-
tions of those expressed predominately in the eye. 
Ocular fluids particularly aqueous and vitreous hu-
mour more reliably reflect the pathophysiological 
mechanisms of DR development however, obtain-
ing these samples may be associated with serious 
complications (21-23,46,51,52). Since tear analysis 
is readily available, it becomes a promising tool for 
biomarker identification. Several studies confirm 
the correlation between the concentration of 
some biomarkers particularly TNF-α and VEGF in 
tears and the degree of DR (53,54). Detection of 
these biomarkers in tears could be a good non-in-
vasive test for early diagnosis and a predictor of 
the severity of DR. To date pro-inflammatory and 
angiogenic molecules are used in basic science 
studies and it is expected that on the basis of ex-
tensive research at least some of these biomarkers 
in the future will be used in routine clinical prac-
tice (47,48). Given the fact that various pro-inflam-
matory and proangiogenic factors particularly 
those that we have evaluated have been implicat-
ed in the pathophysiology of DR this opens up a 
novel area for future investigation of DR biomarker 
detection. 
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